Full Year 2025 Sun Pharmaceutical Industries Ltd Earnings Call Transcript
Key Points
- Sun Pharmaceuticals Industries Ltd (BOM:524715) reported a full-year sales growth of 9% to INR520,412 million, driven by a better product mix and higher sales from the specialty business.
- The company's EBITDA for the year increased by 17.3%, resulting in an EBITDA margin of 29%, indicating strong operational performance.
- India formulation sales grew by 13.7% for the full year, with Sun Pharma maintaining its number one position in the Indian pharmaceutical market with an 8.3% market share.
- The US business saw growth in specialty products, with key brands like Ilumya and Cequa contributing positively, despite a decline in generics.
- Sun Pharmaceuticals Industries Ltd (BOM:524715) continues to invest in R&D, with a focus on building a pipeline for both global generics and specialty businesses, allocating 6.4% of sales to R&D in Q4 FY25.
- The US generics business faced a decline due to increased competition, impacting overall sales in the region.
- The company reported a significant increase in the effective tax rate to 19.8% for Q4 FY25, up from 5.1% in Q4 FY24, with expectations of further increases due to the exhaustion of tax losses.
- Sun Pharmaceuticals Industries Ltd (BOM:524715) incurred exceptional items amounting to INR3,617 million in Q4 FY25, primarily due to an impairment of investment in Lyndra Therapeutics.
- The company anticipates mid to high single-digit consolidated top-line growth for FY26, indicating a potential slowdown compared to previous years.
- There is uncertainty regarding the impact of potential regulatory changes in the US, such as tariffs and Medicare pricing reforms, which could affect future profitability.
Ladies and gentlemen, good day and welcome to Sun Pharma's Q4 FY25 financial results conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Dr. Abhishek Sharma, Vice President and Head of Investor Relations and Strategic Projects. Thank you, and over to you, Dr. Sharma.
Thanks. Thank you. Good evening, and a warm welcome to our fourth-quarter FY25 earnings call. I'm Abhishek from the Sun Pharma Investor Relations team. We hope you have received the Q4 financials and the press release that was sent out earlier in the day. These are also available on our website.
We have with us Mr. Dilip Shanghvi, Chairman and Managing Director; Mr. C.S. Muralidharan, CFO; Mr. Abhay Gandhi, CEO, North America; and Mr. Kirti Ganorkar, CEO, India business.
Today, the team will provide an update on the financial performance and business highlights for the quarter, pipeline updates, and respond to any questions
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
